Does Amerigroup Cover Saxenda? A Complete Coverage Guide

What Is Saxenda and Why Does Coverage Matter?

Saxenda is a once-daily injectable GLP-1 receptor agonist containing liraglutide 3 mg. It is FDA-approved for adults with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. Novo Nordisk's FDA label is on file at the FDA's drug database.

How Saxenda Works

Liraglutide mimics the hormone glucagon-like peptide-1, which slows gastric emptying, increases satiety signaling in the hypothalamus, and reduces caloric intake. In the SCALE Obesity and Prediabetes trial (N=3,731, 56 weeks), liraglutide 3 mg produced a mean weight loss of 8.4% of body weight compared with 2.8% for placebo (P<0.001). [1]

Why the Price Creates a Coverage Crisis

At roughly $1,400 to $1,600 per month out of pocket, Saxenda is unaffordable for most Medicaid beneficiaries without plan coverage. The Obesity Medicine Association notes that fewer than 40 states include any FDA-approved anti-obesity medication on their Medicaid formularies, leaving millions of low-income patients with obesity without access to evidence-based pharmacotherapy. [2]

How Amerigroup's Plan Structure Affects Saxenda Access

Amerigroup, now operating under the Anthem/Elevance Health umbrella, administers Medicaid Managed Care and Medicare Advantage plans across roughly 10 states including Georgia, Maryland, Nevada, New Jersey, New York, Tennessee, Texas, Virginia, and Washington. Each state contract produces a different formulary. There is no single national Amerigroup formulary.

Medicaid Managed Care Plans

Most Amerigroup Medicaid Managed Care plans follow state Medicaid drug policy. If a state's Medicaid program excludes anti-obesity drugs, Amerigroup cannot unilaterally add them to the formulary. As of 2024, the Centers for Medicare and Medicaid Services (CMS) confirmed that federal Medicaid law does not require states to cover weight-loss medications, though CMS has been moving toward expanded coverage guidance. [3]

States where Amerigroup has historically excluded Saxenda from Medicaid formularies include Georgia and Tennessee. States with partial or conditional Medicaid coverage of GLP-1 agents more broadly include New York and New Jersey, though specific formulary tier and step-therapy requirements vary by plan year.

Medicare Advantage Plans

Traditional Medicare Part D has historically excluded drugs used for weight loss under the Medicare Modernization Act's exclusion list. The Treat and Reduce Obesity Act (TROA), reintroduced in Congress multiple times, would change this, but as of early 2025 it has not been enacted. Some Amerigroup Medicare Advantage plans have added supplemental benefits that cover certain GLP-1 agents when prescribed for type 2 diabetes, not for weight loss. Saxenda (liraglutide 3 mg) is distinct from Victoza (liraglutide 1.8 mg), which is approved for type 2 diabetes. Plans that cover Victoza may not cover Saxenda, even though both products contain the same molecule. [4]

Prior Authorization Requirements Amerigroup Typically Applies

Even when Saxenda appears on an Amerigroup formulary, the plan will almost always require prior authorization (PA) before dispensing. Failing to get PA before the first fill results in a claim denial at the pharmacy.

Standard Clinical Criteria

Amerigroup PA criteria for Saxenda commonly include:

• BMI of 30 kg/m² or higher documented in the chart within the prior 12 months
• Alternatively, BMI of 27 kg/m² or higher with a documented comorbidity (type 2 diabetes, hypertension, or obstructive sleep apnea)
• Participation in a structured behavioral weight-management program for at least 6 months prior to the request, with documented failure to achieve clinically meaningful weight loss (usually defined as <5% body weight)
• A prescriber attestation that the patient has received dietary and physical activity counseling

Step Therapy Requirements

Several Amerigroup state plans require step therapy. This means the patient must have tried and failed at least one cheaper first-line intervention before Saxenda will be approved. Some plans require documented trials of phentermine/topiramate extended-release or orlistat before a GLP-1 agent will be authorized. Step therapy rules vary by state and plan year, so checking the current Evidence of Coverage document is the only reliable way to confirm requirements for a specific member.

Duration and Renewal

Initial PA approvals are typically granted for 6 months. Renewal requires documentation that the patient has lost at least 5% of baseline body weight and is still using the medication. If the efficacy threshold is not met, the plan may discontinue coverage at renewal. The FDA label for Saxenda recommends reassessing after 16 weeks; if a patient has not lost at least 4% of body weight by that point on the 3 mg dose, the label states that continued treatment is unlikely to be beneficial. [5]

How to Check Whether Your Specific Amerigroup Plan Covers Saxenda

Step 1: Look Up the Formulary Online

Every Amerigroup plan is required to publish a formulary (drug list) online. Go to the Amerigroup member portal for your state and search for "liraglutide" or "Saxenda." Note the tier, any PA symbol, and any step-therapy symbol. CMS requires Medicare Part D plan sponsors to update formularies annually; checking mid-year may show an outdated document if the plan issued a formulary exception.

Step 2: Call Member Services

Member Services phone numbers appear on the back of the Amerigroup ID card. Ask specifically: "Is Saxenda (liraglutide 3 mg) covered under my formulary? Does it require prior authorization? Does it require step therapy?" Request the answers in writing or ask for a fax number to send a PA request to.

Step 3: Have Your Prescriber Submit a PA Request

The prescriber's office submits PA requests directly to Amerigroup. The request should include the chart-documented BMI, list of comorbidities, and records showing participation in a behavioral weight-management program. CMS guidelines require that standard PA decisions be issued within 72 hours, and urgent PA decisions within 24 hours for Medicare Advantage plans. [6]

What to Do If Amerigroup Denies Saxenda Coverage

Denials are not final. Medicaid and Medicare Advantage members have the right to appeal. The appeal process follows a specific timeline and format that differs between Medicaid and Medicare Advantage.

For Medicaid Members

State Medicaid fair hearing rights apply. The member (or an authorized representative) can request a fair hearing within the timeframe specified in the denial notice, which varies by state but is commonly 30 to 90 days from the date of the denial letter. Requesting a fair hearing while continuing the drug on a provisional basis is sometimes possible if the patient was already receiving coverage and the plan is discontinuing it.

For Medicare Advantage Members

Medicare Advantage members can request a coverage determination, then a redetermination, then an Independent Review Entity (IRE) review, and ultimately a hearing before an Administrative Law Judge if the amount in controversy exceeds the threshold set by CMS (currently $180 for 2024). [7] The Medicare appeals process is governed by regulations at 42 CFR Part 422 and is published on the CMS website.

Exception Requests and Letters of Medical Necessity

A well-documented letter of medical necessity from a treating physician can tip a borderline PA or appeal in the patient's favor. The Obesity Medicine Association recommends that letters of medical necessity document:

1. Current BMI with a date-stamped measurement
2. Specific comorbidities and their severity
3. Prior weight-loss interventions and the degree of response or failure
4. The clinical rationale for selecting Saxenda over cheaper alternatives

Including published outcome data strengthens the argument. The SCALE Obesity and Prediabetes trial demonstrated that liraglutide 3 mg produced clinically meaningful weight reduction in patients with prediabetes and reduced the rate of progression to type 2 diabetes by 80% over 3 years compared with placebo (P<0.001). [1]

Alternatives If Amerigroup Will Not Cover Saxenda

Other GLP-1 Agents on Formulary

Amerigroup plans that cover GLP-1 agonists for type 2 diabetes (rather than obesity) may already cover semaglutide 0.5 mg or 1 mg (Ozempic) or liraglutide 1.2 to 1.8 mg (Victoza) on lower tiers. If a patient has type 2 diabetes and obesity, the prescriber may choose to prescribe a diabetes-approved GLP-1 that also produces weight loss as a secondary benefit.

Wegovy (semaglutide 2.4 mg), which is FDA-approved for chronic weight management, produced a mean weight loss of 14.9% over 68 weeks in STEP-1 (N=1,961) compared with 2.4% for placebo (P<0.001). [8] Some Amerigroup plans that cover Wegovy may not cover Saxenda, and vice versa. Checking the formulary for both drugs is worthwhile.

Tirzepatide (Zepbound)

Zepbound (tirzepatide 2.5 to 15 mg weekly) received FDA approval for chronic weight management in November 2023. In the SURMOUNT-1 trial (N=2,539, 72 weeks), the 15 mg dose produced a mean weight loss of 20.9% of body weight compared with 3.1% for placebo (P<0.001). [9] Zepbound's formulary status on Amerigroup plans is evolving; checking the current formulary is necessary.

Novo Nordisk Patient Assistance

Novo Nordisk, the maker of Saxenda, offers the "Saxenda Savings Card" for commercially insured patients, which can reduce the monthly cost to as low as $25 for eligible patients. For uninsured or underinsured patients, the Novo Nordisk Patient Assistance Program (NovoCare) may provide Saxenda at no cost. The income thresholds and application process are described at the NovoCare program page. [10]

Telehealth and Compounded Options

Several telehealth platforms prescribe compounded semaglutide or tirzepatide at lower price points for patients who cannot access branded GLP-1 agents through insurance. The FDA has issued guidance on compounded drug products and advises patients to be cautious about the quality of compounded GLP-1 medications. [11] Patients considering compounded options should confirm the pharmacy is an FDA-registered 503B outsourcing facility or a state-licensed 503A pharmacy operating under a valid prescription.

The Amerigroup Saxenda Coverage Decision Framework

The following decision path summarizes the coverage-access sequence for a patient trying to obtain Saxenda through an Amerigroup plan.

Step 1. Confirm eligibility criteria. Document BMI 30+ (or BMI 27+ with comorbidity) in the chart before submitting any PA request.

Step 2. Check the formulary. Search the current Amerigroup formulary for liraglutide and Saxenda by name. Note the tier, PA requirement, and any step-therapy requirement.

Step 3. Complete step therapy if required. If the plan mandates a prior trial of phentermine/topiramate or orlistat, ensure those trials are documented in the chart with dates, doses, and degree of response.

Step 4. Submit a complete PA with a letter of medical necessity. The prescriber should include chart-documented BMI, comorbidities, behavioral program participation, and published outcome data.

Step 5. Appeal a denial within the statutory window. For Medicaid, request a state fair hearing. For Medicare Advantage, follow the five-level Medicare appeals process.

Step 6. Explore alternatives simultaneously. Apply for NovoCare patient assistance while the appeal is pending. Ask the prescriber whether a diabetes-approved GLP-1 is clinically appropriate as an interim option.

Clinical Context: Why Access to Anti-Obesity Medications Matters

Obesity is a chronic, relapsing metabolic disease, not a lifestyle choice. The American Heart Association, American College of Cardiology, and the Obesity Society jointly classify obesity as a complex disease requiring multimodal treatment including pharmacotherapy when appropriate. [12] Restricting access to FDA-approved treatments on insurance formularies is therefore a clinical concern, not merely an administrative one.

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease and obesity but without diabetes, compared with placebo (HR 0.80; 95% CI 0.72 to 0.90; P<0.001). [13] This cardiovascular outcome evidence is actively shifting payer policy. As of 2025, CMS proposed expanding Medicare Part D coverage of anti-obesity medications following the SELECT trial results, which may eventually affect Amerigroup Medicare Advantage formularies. [3]

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Antiobesity medications are recommended as adjuncts to lifestyle therapy in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity." [14] Plans that categorically exclude anti-obesity medications contradict this guideline.